Reliability of the Siemens Enzygnost and Novagnost Epstein–Barr Virus assays for routine laboratory diagnosis: agreement with clinical diagnosis and comparison with the Merifluor Epstein–Barr Virus immunofluorescence assay

BMC Infectious Diseases

Table 8 Overall agreement of sample results for the Enzygnost, Novagnost, and Merifluor assays with the established EBV status, including 95% confidence intervals (95% CI)

	% agreement with established EBV status
	Negative (N = 39)	Acute infection (N = 15)	Past infection (N = 464)
	[95% CI]	[95% CI]	[95% CI]
Enzygnost	100	100	99.1
Enzygnost	[90.97% – 100%]	[78.2% – 100%]	[97.81% – 99.75%]
Novagnost	89.7	100	86^a, 98.8^b
Novagnost	[75.78% – 97.13%]	[78.2% – 100%]	[82.5% – 89.02%]^a, [97.1% to 99.6%]^b
Merifluor IFA	92.3	100	98.1
Merifluor IFA	[79.13% – 98.38%]	[78.2% – 100%]	[96.35% – 99.11%]